Table 2. Safety and feasibility data of different studies in patients with NSCLC.
| Studies | Year | No. of patients | TRAEs, n (%) | 3–4 irAEs, n (%) | Resectable patients, n (%) | Surgery delay, n (%) | Complications, n (%) | MPR, n (%) | pCR, n (%) | ORR, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Bott | 2019 | 22 | 2 (9.1) | 1 (4.5) | 20 (90.9) | 0 (0) | 10 (50.0) | 9 (45.0) | NR | 2 (9.1) |
| Cascone | 2021 | 44 | 3 (6.8) | 2 (4.5) | 39 (88.6) | NR | NR | 13 (33.3) | 8 (20.5) | 9 (20.5) |
| Chen T | 2021 | 12 | 4 (33.3) | 0 (0) | 12 (100.0) | 0 (0) | 3 (25.0) | 9 (75.0) | 5 (41.7) | 6 (50.0) |
| Chen Y | 2021 | 35 | 1 (2.9) | 1 (2.9) | 35 (100.0) | 0 (0) | 0 (0) | 26 (74.3) | 18 (51.4) | 17 (48.6) |
| Forde | 2018 | 21 | 5 (23.8) | 1 (4.8) | 20 (95.2) | 0 (0) | NR | 9 (45.0) | 3 (15.0) | 2 (9.5) |
| Gao | 2020 | 40 | 21 (52.5) | 4 (10.0) | 37 (92.5) | 2 (5.4) | 4 (10.8) | 15 (40.5) | 9 (24.3) | 8 (21.6) |
| Liu | 2020 | 13 | 12 (92.3) | 0 (0) | 5 (38.5) | 0 (0) | 5 (100.0) | 3 (60.0) | 1 (20.0) | 8 (61.5) |
| Lücke | 2020 | 4 | 0 (0) | 0 (0) | 4 (100.0) | 0 (0) | 0 (0) | 2 (50.0) | 2 (50.0) | 3 (75.0) |
| Provencio | 2020 | 46 | 43 (93.5) | 14 (30.4) | 41 (89.1) | 0 (0) | 12 (29.3) | 34 (82.9) | 26 (63.4) | 35 (76.1) |
| Reuss | 2020 | 9 | 6 (66.7) | 3 (33.3) | 6 (66.7) | 0 (0) | 1 (16.7) | 2 (33.3) | 2 (33.3) | 1 (16.7) |
| Shu | 2020 | 30 | 26 (86.7) | 3 (10.0) | 26 (86.7) | 0 (0) | 13 (50.0) | 17 (65.4) | 10 (38.5) | 19 (63.3) |
| Tfayli | 2020 | 15 | 4 (26.7) | 4 (26.7) | 11 (73.3) | 0 (0) | 0 (0) | 3 (27.3) | 1 (9.1) | 4 (26.7) |
| Rothschild | 2021 | 67 | 67 (100.0) | 59 (88.1) | 55 (82.1) | NR | 2 (3.6) | 34 (61.8) | 10 (18.2) | 29 (43.3) |
NSCLC, non-small-cell lung cancer; No., number; TRAEs, treatment-related adverse events; irAEs, immune-related adverse events; MPR, major pathologic response; pCR, pathological complete response; ORR, objective response rate; NR, not related.